Antibe Therapeutics (TSX:ATE) Pre-Tax Income : C$-18.24 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Antibe Therapeutics's pretax income for the three months ended in Dec. 2023 was C$-4.21 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was C$-18.24 Mil. Antibe Therapeutics's pretax margin was %.

During the past 12 years, Antibe Therapeutics's highest Pretax Margin was -67.50%. The lowest was -22005.00%. And the median was -111.74%.

Antibe Therapeutics Pre-Tax Income Historical Data

The historical data trend for Antibe Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Pre-Tax Income Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Pre-Tax Income

Get a 7-Day Free Trial

-12.68

-19.05

-23.85

-25.25

-19.29

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-4.21	-3.24	-5.79	-5.01	-4.21

Competitive Comparison of Antibe Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Antibe Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Pre-Tax Income falls into.

Antibe Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Antibe Therapeutics's Pretax Income for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-20.546	+	-0.09	+	-0.008	+	1.353	+	-3.5527136788005E-15
	=	-19.29

Antibe Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-4.596	+	-0.003	+	-0.002	+	0.388	+	0
	=	-4.21

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-18.24 Mil.

Antibe Therapeutics (TSX:ATE) Pre-Tax Income Explanation

Antibe Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-4.213	/	0
	=	%

During the past 12 years, Antibe Therapeutics's highest Pretax Margin was -67.50%. The lowest was -22005.00%. And the median was -111.74%.

Antibe Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines